MAPK
Showing all 6 results
-
Approved Drugs
Binimetinib | MEK1/2 inhibitor
Binimetinib (606143-89-9) is a potent (IC50 = 12 nM) and selective allosteric inhibitor of MEK1/2.1,2 Recently approved by the FDA for treatment of...$39.00 – $115.00 Select options -
Kinases
GW-5074 | c-Raf1 inhibitor
GW-5074 (220904-83-6) is a potent inhibitor of cRAF1 kinase (IC50 = 9 nM). Displays 100-fold selectivity for cRAF1 over CDK1, CDK2, c-src, ERK2, ME...$50.00 – $175.00 Select options -
Cancer
Hypothemycin | MEK inhibitor
Hypothemycin (76958-67-3) is a potent and selective inhibitor of MEK.1-3 Acts via covalent binding to Cys residue.2 In cells, hypothemycin inhibits...$200.00 Select options -
Cancer
PD-98059 | MEK inhibitor
PD-98059 (167869-21-8) is an inhibitor of mitogen-activated protein kinase kinase (MKK / MEK). Acts via binding to the inactivated form of MEK, pre...$45.00 – $160.00 Select options -
Angiogenesis
Sorafenib | Multi-kinase inhibitor
Sorafenib (475207-59-1) was initially developed as a Raf kinase inhibitor, IC50 = 6 nM, but has been shown to inhibit many receptor tyrosine kinase...$40.00 – $160.00 Select options -
Cancer
U0126 | Selective MEK1 and MEK2 inhibitor
U0126 (109511-58-2) is a highly selective inhibitor of MEK1 and MEK2 in vitro and in vivo. Unlike PD98059 (Cat.# 10-2159), which only inhibits the ...$90.00 – $190.00 Select options
